Stomach cancer, though not as common as some other forms of cancer, can be a serious and life-threatening condition if not ...

Stomach cancer, though not as common as some other forms of cancer, can be a serious and life-threatening condition if not ...

Rare gastrointestinal lesions are seldom seen in endoscopy, limiting data for AI and clinician training. Here, authors present EndoRare, a one-shot retraining-free framework that synthesizes diverse ...

Shares of ArriVent BioPharma rose after the company announced positive initial data from a Phase 1 trial of treatment for gastrointestinal cancers. The stock gained 9.3% to $22.95 in premarket trading ...

A breakthrough treatment has made significant progress, showing promising results in decreasing recurrence and death from a ...

FDA approves Tukysa maintenance therapy with Herceptin and Perjeta, extending progression-free survival by over eight months ...

AstraZeneca ( AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, ...

Two Phase 3 trials presented at Europe's leading oncology conference show major survival gains: Roche's divarasib outperforms ...

Global Fabry Disease Market size is expected to be worth around US$ 5.3 Billion by 2034 from US$ 2.5 Billion in 2024.

Scientists have discovered that a potential new drug can reverse severe fatty liver disease in animal models by restoring gut ...

"Doctor, I've been taking this stomach medicine for about 10 years now. Is that okay?"I am often asked this during outpatient ...

GLP-1 receptor agonists support weight loss and metabolic control in people with inflammatory bowel disease, while ...